Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Publication year range
2.
J Pharmacol Sci ; 114(1): 1-5, 2010.
Article in English | MEDLINE | ID: mdl-20716857

ABSTRACT

Schizophrenia is a debilitating and complex mental disorder with a prevalence of approximately 1% worldwide. The etiology remains unclear, despite massive research efforts. Hyperactive dopaminergic signal transduction in the central nervous system is suggested to be involved in the pathophysiology of schizophrenia (the dopamine hypothesis). The dopamine D(2)-receptor (DRD2) gene is thus a promising candidate for associations with risk of schizophrenia. We investigated DRD2 and found a novel missense nucleotide change causing an amino acid substitution of serine with cysteine at codon 311 (Ser311Cys). We performed an association study using 156 schizophrenia patients and 300 controls. Cys311 in DRD2 was significantly associated with schizophrenia. Patients with the Cys311 allele displayed shorter duration of hospitalization and less severe negative symptoms and were more frequently married compared to patients without this allele, suggesting good response to treatment. We expanded samples to 291 patients with schizophrenia (including 11 postmortem brain samples), 579 controls, and 78 patients with affective disorders in a further case-control study. Cys311 was associated with schizophrenia, particularly in patients without negative symptoms, and bipolar disorder with mood-incongruent psychotic symptoms. Three meta-analyses using over 20 published studies confirmed the association. In vitro studies showed that Cys311-type D(2) receptor impairs dopamine-induced sequestration, which appears to be consistent with the dopamine hypothesis.


Subject(s)
Dopamine/physiology , Drug Discovery/methods , Polymorphism, Genetic/genetics , Receptors, Dopamine D2/genetics , Receptors, Dopamine D2/physiology , Schizophrenia/drug therapy , Schizophrenia/genetics , Alleles , Animals , Cysteine/genetics , Humans , Mental Disorders/drug therapy , Mental Disorders/genetics , Mental Disorders/metabolism , Schizophrenia/metabolism , Serine/genetics , Signal Transduction/drug effects , Signal Transduction/genetics
5.
Pharmacogenetics ; 13(5): 271-8, 2003 May.
Article in English | MEDLINE | ID: mdl-12724619

ABSTRACT

Hypofunction of the N-methyl-D-aspartate (NMDA) receptor has been hypothesized to underlie the pathophysiology of schizophrenia, based on the observation that non-competitive antagonists of the NMDA receptor, such as phencyclidine, induce schizophrenia-like symptoms. Mice lacking the NR2A subunit of the NMDA receptor complex are known to display abnormal behaviour, similar to schizophrenic symptoms. The expression of NR2A starts at puberty, a period corresponding to the clinical onset of schizophrenia. This evidence suggests that the NR2A (GRIN2A) gene may play a role in the development of schizophrenia and disease phenotypes. In this study, we performed a genetic analysis of this gene in schizophrenia. Analysis of the GRIN2A gene detected four single nucleotide polymorphisms, and a variable (GT)(n) repeat in the promoter region of the gene. A case-control study (375 schizophrenics and 378 controls) demonstrated evidence of an association between the repeat polymorphism and the disease (P = 0.05, Mann-Whitney test), with longer alleles overly represented in patients. An in-vitro promoter assay revealed a length dependent inhibition of transcriptional activity by the (GT)(n) repeat, which was consistent with a receptor binding assay in postmortem brains. Significantly, the score of symptom severity in chronic patients correlated with repeat size (P = 0.01, Spearman's Rank test). These results illustrate a genotype-phenotype correlation in schizophrenia and suggest that the longer (GT)(n) stretch may act as a risk-conferring factor that worsens chronic outcome by reducing GRIN2A levels in the brain.


Subject(s)
Gene Expression Regulation/genetics , Microsatellite Repeats/genetics , Polymorphism, Genetic/genetics , Polymorphism, Single Nucleotide/genetics , Receptors, N-Methyl-D-Aspartate/genetics , Schizophrenia/genetics , Transcription, Genetic/genetics , Adult , Aged , Base Sequence , DNA Primers , DNA, Complementary/genetics , Female , Humans , Male , Middle Aged , Prognosis , Reference Values , Treatment Outcome
6.
Am J Med Genet B Neuropsychiatr Genet ; 118B(1): 20-4, 2003 Apr 01.
Article in English | MEDLINE | ID: mdl-12627459

ABSTRACT

Dysregulation in dopaminergic neurotransmission might play a role in the pathogenesis of schizophrenia, and therefore genetic components of the dopamine (DA) pathway may confer risk. The NR4A2 (Nurr1) gene is essential for the development and maintenance of mesencephalic DA-synthesizing neurons. Moreover, Nurr1 forms a heterodimer with the retinoid X receptor and disturbances in the retinoid-signaling cascade may be involved in susceptibility to schizophrenia. To investigate the potential genetic contribution of NR4A2, we performed a case-control association study using three common variants in the gene [-2922(C)2-3, IVS6 + 17 approximately +18insG, EX8 + 657(CA)9-10] that were in strong linkage disequilibrium with each other. We did not detect a significant allelic or genotypic association. Haplotypes derived from all three polymorphisms generated similar results. These data do not support the notion that the NR4A2 gene plays a major role in risk for schizophrenia among Japanese individuals.


Subject(s)
DNA-Binding Proteins/genetics , Schizophrenia/genetics , Transcription Factors/genetics , Adult , Case-Control Studies , Female , Gene Frequency , Genotype , Haplotypes , Humans , Japan , Linkage Disequilibrium , Male , Middle Aged , Mutation , Nuclear Receptor Subfamily 4, Group A, Member 2 , Polymorphism, Genetic
7.
Psychiatry Res ; 109(1): 93-6, 2002 Jan 31.
Article in English | MEDLINE | ID: mdl-11850055

ABSTRACT

Platelet-activating factor (PAF) is a potent phospholipid mediator that plays various roles in neuronal function and brain development. It is involved in NMDA receptor function. Release and degradation of PAF is controlled by intracellular and plasma PAF-acetylhydrolase (PAFAH). The plasma PAFAH gene (PLA2G7) is located on chromosome 6p. A previous study showed weak associations of the Ile198Thr and Val379Ala polymorphisms of this gene with schizophrenia that did not reach statistical significance after correction for multiple comparisons. Another study showed that a functional alteration of the enzyme with these two polymorphisms is likely, but the magnitude may be modest. Approximately 4% of the Japanese population lack plasma PAFAH because of a loss-of-function mutation (Val279Phe) in the PAFAH gene. Thus, the Val279Phe mutation is useful for examining whether a causal relation exists between PAFAH function and schizophrenia. We looked for an association between the Val279Phe mutation and schizophrenia in 191 Japanese patients with schizophrenia and in 188 Japanese controls. Similar genotypic and allelic distributions were observed in the two groups. These observations indicate that functional differences in the plasma form of PAFAH do not play a substantial role in the etiology of schizophrenia. However, the present study leaves open the possibility that other isoforms are involved.


Subject(s)
Phospholipases A/deficiency , Schizophrenia/metabolism , 1-Alkyl-2-acetylglycerophosphocholine Esterase , Acetyltransferases/deficiency , Acetyltransferases/genetics , Adult , Aged , Case-Control Studies , Female , Gene Frequency/genetics , Genotype , Humans , Male , Middle Aged , Phospholipases A/genetics , Point Mutation/genetics , Receptors, N-Methyl-D-Aspartate/metabolism , Schizophrenia/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...